Brand names: Vonjo
Kinase Inhibitor · Tyrosine Kinase Inhibitors · Janus Kinase Inhibitors · Cytochrome P450 1A2 Inhibitors · Cytochrome P450 3A4 Inhibitors · P-Glycoprotein Inhibitors · Breast Cancer Resistance Protein Inhibitors · Organic Cation Transporter 1 Inhibitors
2 interactions on record
Monitor patients concomitantly receiving moderate CYP3A4 inhibitors (e.g., fluconazole) for increased adverse reactions and consider VONJO dose modifications based on safety [see Dosage and Administration ( 2.5 )] . Concomitant use of VONJO with doses of fluconazole greater than 200 mg once daily has not been studied.
Source: FDA drug label - pacritinib
Rosuvastatin: The dose of rosuvastatin should not exceed 20 mg once daily when concomitantly used with VONJO [see Clinical Pharmacology ( 12.3 )] .
Source: FDA drug label - pacritinib